Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model
Authors:
- J BlaserJBJ Blaser
- B B StoneBSB B Stone
- M C GronerMGM C Groner
- S H ZinnerSZS H Zinner
Open Access
- 1 July 1985
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 28 (1) , 64-68
Abstract
The antibacterial activities of ceftazidime and netilmicin were studied in a two-compartment in vitro model. Pseudomonas aeruginosa cultures were exposed to changing drug concentrations that mimic human pharmacokinetics. Netilmicin alone reduced the numbers of organisms in cultures of the susceptible strains by more than 99% within 4 h; however, regrowth occurred after 8 h. Although ceftazidime alone killed more slowly than netilmicin, only one of the five strains regrew within 28 h. When both drugs were combined, rapid initial killing occurred without subsequent regrowth. Studied after 24 h in combination with ceftazidime, netilmicin was as effective when given as a single daily dose as when administered in three daily doses that provided 50% more aminoglycoside per day. Decreased bacterial susceptibility was seen after ceftazidime exposure for one strain and after netilmicin exposure for all originally netilmicin-susceptible strains. No such reduction in susceptibility was observed during exposure to the combination. The results of standard in vitro checkerboard tests for synergism were predictive of the initial (4 to 8 h) but not the final (24 to 28 h) assessment of drug interaction in the pharmacokinetic model.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro modelAntimicrobial Agents and Chemotherapy, 1985
- Two compartment kinetic model with multiple artificial capillary unitsJournal of Antimicrobial Chemotherapy, 1985
- Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopeniaAntimicrobial Agents and Chemotherapy, 1984
- Ceftazidime versus Tobramycin/Ticarcillin in Treating Hospital Acquired Pneumonia and BacteremiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1984
- High-Performance Liquid Chromatographic Determination of Ceftazidime in Serum, Urine, CSF, and Peritoneal Dialysis FluidJournal of Liquid Chromatography, 1984
- Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patientsJournal of Antimicrobial Chemotherapy, 1983
- Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy, 1983
- Monotherapie von systemischen Pseudomonas-aeruginosa-Infektionen mit Ceftazidim: Ursachen therapeutischer MißerfolgeDMW - Deutsche Medizinische Wochenschrift, 1983
- Biological variability of multiple dose pharmacokinetics of netilmicin in manEuropean Journal of Clinical Pharmacology, 1983
- Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and CeftazidimeAntimicrobial Agents and Chemotherapy, 1981